2022
Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve
Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and Learning Curve. Journal Of Endourology 2022, 36: 1285-1289. PMID: 35906798, PMCID: PMC9587764, DOI: 10.1089/end.2021.0885.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyShort-term outcomesCase seriesRadical prostatectomyAcceptable short-term outcomesSurgeon 2Average prostate weightLearning curveMedian patient ageClavien-Dindo scaleMedian operating timeTotal postoperative complicationsShorter hospital stayLarge case seriesOperating timeProstate-specific antigenRobotic radical prostatectomyInstitutional review boardSignificant learning curveHospital stayMedian followPostoperative complicationsIntraoperative complicationsPerioperative outcomesBlood loss
2021
Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series
Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis K, Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series. Journal Of Urology 2021, 206: 1184-1191. PMID: 34181471, DOI: 10.1097/ju.0000000000001939.Peer-Reviewed Original ResearchConceptsRobotic-assisted radical prostatectomyAssisted radical prostatectomyConsole timeRadical prostatectomyPrimary treatmentStereotactic body radiation therapyFeasible salvage optionNonsurgical primary treatmentPostoperative pad useUrinary function outcomesRisk of incontinenceKaplan-Meier curvesBody radiation therapyProportional hazards modelLonger console timeT-testStudent's t-testPostoperative complicationsMedian followupOncologic outcomesPerioperative dataBlood lossComplication rateSalvage optionFunction outcomes
2020
Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture
Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a γ-Tocopherol-Rich Vitamin E Mixture. Nutrition And Cancer 2020, 73: 2740-2750. PMID: 33319628, PMCID: PMC8670097, DOI: 10.1080/01635581.2020.1857412.Peer-Reviewed Original ResearchConceptsVitamin E mixtureProstate tissue levelsUrine samplesReported adverse eventsDay of surgeryProstate cancer patientsPhase 0 trialsDays of supplementationCancer preventive activityAdverse eventsBlood lossTreatment armsUrine levelsCancer patientsRadical prostatectomyAnimal modelsVitamin EProstate tissueTissue levelsPreventive activitiesProstate levelsSupplementationPatientsProstatectomySurgeryThe cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer
Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. BJU International 2020, 125: 792-800. PMID: 32176456, DOI: 10.1111/bju.15055.Peer-Reviewed Original ResearchConceptsHormone-sensitive metastatic prostate cancerMetastatic prostate cancerCytoreductive prostatectomyAndrogen deprivation therapyProstate cancerOverall survivalRadical prostatectomyLimited bone metastasesCancer-specific outcomesLocal treatment optionsProgression-free survivalDiagnosis of metastasisPrimary outcome measureNovel treatment algorithmOligometastatic settingAdjuvant treatmentMetastatic settingSecondary endpointsCastration resistanceMetastatic diseaseStandard therapyBone metastasesDefinitive treatmentOngoing trialsTreatment algorithmEDITORIAL COMMENT
Sterling J, Jang T, Kim I. EDITORIAL COMMENT. Urology 2020, 135: 122. PMID: 31895674, DOI: 10.1016/j.urology.2019.07.052.Peer-Reviewed Original Research
2017
Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy
Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyPT3 prostate cancerRobot-assisted radical prostatectomyPathologic Gleason scoreBiochemical recurrenceRadical prostatectomyClinical progressionProstate cancerLymphovascular invasionRisk stratificationRisk factorsDisease progressionMultivariate Cox proportional regression analysisCox proportional regression analysisAdverse pathologic featuresProportional regression analysisRisk stratification toolMore risk factorsStage pT3bFree survivalOncologic outcomesPathologic featuresStratification toolGleason scoreOptimal patient
2015
Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer
Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer. Journal Of Urology 2015, 195: 1464-1470. PMID: 26608903, PMCID: PMC5769700, DOI: 10.1016/j.juro.2015.11.031.Peer-Reviewed Original ResearchConceptsFavorable-risk prostate cancerRisk prostate cancerProstate-specific antigenProstate cancerSpecific antigenActive surveillancePathological outcomesAntigen groupRadical prostatectomyBiochemical recurrence-free survival rateElevated prostate-specific antigenProstate specific antigen cutoffLow-risk prostate cancerProstate-specific antigen levelRecurrence-free survival ratesFavorable risk diseaseMulti-institution databaseSpecific antigen levelsAdverse pathological outcomesTreatment of choiceDatabase of menHigh groupOncologic outcomesRisk diseaseAntigen levelsLower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics
Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal Of Korean Medical Science 2015, 30: 937-942. PMID: 26130958, PMCID: PMC4479949, DOI: 10.3346/jkms.2015.30.7.937.Peer-Reviewed Original ResearchConceptsProstate cancerClinicopathological characteristicsElevated prostate-specific antigen levelsProstate-specific antigen levelBenign prostatic hyperplasia patientsNon-metastatic diseaseAggressive clinicopathologic featuresLow PSA levelsSpecific antigen levelsProstatic hyperplasia patientsAggressive clinicopathological characteristicsLow Gleason scoreHuman prostate cancerCharacteristic curve analysisProstate cancer susceptibilityPSA levelsMetastatic diseasePCa patientsClinicopathologic featuresHyperplasia patientsAntigen levelsGleason scoreClinicopathological parametersPCa tissuesReal-time PCR
2013
Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer
Kang H, Yang J, Kwon W, Lee Y, Kim W, Kim Y, Yun S, Lee S, Kim I, Kim W. Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer. Journal Of Korean Medical Science 2013, 28: 1796-1800. PMID: 24339711, PMCID: PMC3857377, DOI: 10.3346/jkms.2013.28.12.1796.Peer-Reviewed Original ResearchConceptsProstate-specific antigen densityTUR specimensElderly patientsPSA levelsGleason scoreProstate cancerBiopsy coresHigher prostate-specific antigen levelProstate-specific antigen levelElderly comorbid patientsRoutine prostate biopsySignificant co morbiditySpecific antigen densityHigh clinical suspicionSpecific antigen levelsProstatic needle biopsyPrebiopsy PSA levelProstate cancer diagnosisTUR specimenClinical suspicionCo morbiditiesPathologic reviewComorbid patientsTransurethral resectionAntigen levelsUse of a Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier on the Neurovascular Bundle and Prostatic Bed to Facilitate Earlier Recovery of Erectile Function After Robot-Assisted Prostatectomy: An Initial Experience
Joung J, Ha Y, Singer E, Ercolani M, Favaretto R, Lee D, Kim W, Lee K, Kim I. Use of a Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier on the Neurovascular Bundle and Prostatic Bed to Facilitate Earlier Recovery of Erectile Function After Robot-Assisted Prostatectomy: An Initial Experience. Journal Of Endourology 2013, 27: 1230-1235. PMID: 23879531, PMCID: PMC3787401, DOI: 10.1089/end.2013.0345.Peer-Reviewed Original ResearchConceptsRobot-assisted radical prostatectomyErectile functionNeurovascular bundleEF recoveryEarly recoveryPerioperative complicationsIndependent predictorsRadical prostatectomyGroup 2Group 1Initial experienceBilateral nerve-sparing techniqueNerve-sparing robot-assisted radical prostatectomyEF recovery ratesPreoperative IIEF-5Preoperative International IndexPreoperative sexual functionNerve-sparing techniqueRobot-Assisted ProstatectomyIIEF-5Consecutive patientsProstatic bedSurgical outcomesProstate removalSexual functionIncreased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance
Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Active Surveillance. Urology 2013, 81: 831-836. PMID: 23465143, PMCID: PMC3978180, DOI: 10.1016/j.urology.2012.12.046.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer NetworkAA menRadical prostatectomyActive surveillanceProstate cancerNCCN criteriaBiopsy coresAS criteriaAS inclusion criteriaFinal surgical pathologyComprehensive Cancer NetworkPositive biopsy coresDatabase of menWorse clinicopathological featuresAfrican American menPathological upstagingAdvanced diseaseIndependent predictorsPathologic characteristicsClinicopathological featuresPreoperative PSAClinicopathologic findingsWA patientsInclusion criteriaPositive cores
2011
Pathologic implications of prostatic anterior fat pad
Jeong J, Choi E, Kang D, Ercolani M, Lee D, Kim W, Kim I. Pathologic implications of prostatic anterior fat pad. Urologic Oncology Seminars And Original Investigations 2011, 31: 63-67. PMID: 21396837, DOI: 10.1016/j.urolonc.2010.09.003.Peer-Reviewed Original ResearchConceptsProstatic anterior fat padRobot-assisted radical prostatectomyMetastatic prostate cancerLymph nodesProstate cancerAnterior fat padPSA levelsRadical prostatectomyLymphoid tissuePathologic analysisFat padPathologic implicationsSignificant pathologic differencesHigh-risk featuresPelvic lymph nodesRetrospective chart reviewLymph node statusProstate cancer patientsChart reviewConsecutive patientsPathologic stagingRoutine excisionNode statusBiochemical recurrenceCancer patients
2009
Functional and Oncologic Outcomes Comparing Interfascial and Intrafascial Nerve Sparing in Robot-Assisted Laparoscopic Radical Prostatectomies
Potdevin L, Ercolani M, Jeong J, Kim I. Functional and Oncologic Outcomes Comparing Interfascial and Intrafascial Nerve Sparing in Robot-Assisted Laparoscopic Radical Prostatectomies. Journal Of Endourology 2009, 23: 1479-1484. PMID: 19694530, DOI: 10.1089/end.2009.0369.Peer-Reviewed Original ResearchConceptsRobot-assisted laparoscopic radical prostatectomyNerve sparingLaparoscopic radical prostatectomyInterfascial groupRadical prostatectomyAir groupPotency ratesBilateral nerve sparing procedureNerve sparing procedurePositive surgical marginsPT2 diseasePerioperative characteristicsContinence ratesPostoperative outcomesPT3 diseaseSparing proceduresComplication rateSurgical marginsImproved outcomesInterfascial techniqueRobotic approachPatientsProstatectomySparingStudy period
2004
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells
Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.Peer-Reviewed Original ResearchConceptsBone morphogenetic proteinProstate cancer cellsHuman prostate cancer cellsLoss of expressionProstate cancer patientsBMP-RIICancer patientsGleason scoreBMP receptor type IABone morphogenetic protein receptor type IICancer cellsSignificant associationHuman prostate cancer cell linesBiochemical recurrence-free rateExpression of BMPRsRecurrence-free rateProstate cancer cell linesCell linesTumor growth rateReceptor type IIParental cell lineCancer cell linesMorphogenetic proteinsClinical stagePrognostic valueTissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy
Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-β1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 2004, 63: 1191-1197. PMID: 15183988, DOI: 10.1016/j.urology.2003.12.015.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedDisease ProgressionFollow-Up StudiesHumansImmunohistochemistryMaleMiddle AgedMultivariate AnalysisNeoplasm StagingProstateProstatectomyProstate-Specific AntigenProstatic HyperplasiaProstatic NeoplasmsReceptors, Transforming Growth Factor betaTransforming Growth Factor betaTransforming Growth Factor beta1ConceptsPlasma TGF-beta1 levelsTGF-beta1 levelsAbnormal expressionTGFbeta-RIITGFbeta-RIBiochemical progressionRadical prostatectomyProstate cancerPathologic Gleason scoreSeminal vesicle involvementSurgical margin statusProstate cancer featuresTissue expressionGrowth factor-β1TGF-beta1 overexpressionConsecutive patientsExtracapsular diseaseMargin statusPathologic featuresGleason scoreBlood levelsLoss of expressionPrognostic markerImmunohistochemical stainingFactor-β1
2000
Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)‐TGF‐β type II dominant negative receptor
Kundu S, Kim I, Yang T, Doglio L, Lang S, Zhang X, Buttyan R, Kim S, Chang J, Cai X, Wang Z, Lee C. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)‐TGF‐β type II dominant negative receptor. The Prostate 2000, 43: 118-124. PMID: 10754527, DOI: 10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IAnimalsApoptosisGenes, DominantGenomeImmunohistochemistryMaleMiceMice, TransgenicOrgan SizePromoter Regions, GeneticProstateProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IReceptors, AndrogenReceptors, Transforming Growth Factor betaTestosteroneConceptsVentral prostateEpithelial cellsAnimal prostatesDominant negative receptorTransgenic miceNegative receptorProstate-specific promotersProstatic epithelial cellsTransgenic mouse systemTGF-beta resultsSerum levelsTGF-beta signalingProstate growthProstatic growthNormal prostateAndrogenic statusProstateProximal ductExperimental modelLoss of apoptosisInhibitory effectMouse systemSignificant differencesAbnormal morphologyLoss of sensitivity
1998
Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.
Kim I, Ahn H, Lang S, Oefelein M, Oyasu R, Kozlowski J, Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clinical Cancer Research 1998, 4: 1625-30. PMID: 9676836.Peer-Reviewed Original ResearchConceptsHuman prostate cancer tissuesClinical tumor stageProstate cancer patientsProstate cancer tissuesGleason scoreLoss of expressionTGF-betaRIRecurrence rateTumor stageCancer patientsRadical prostatectomyCancer tissuesSurvival rateSignificant associationPotential prognostic valuePotential prognostic markerReceptor type IGrowth factor betaGrowth factor beta receptorTGF-beta receptorsInitial diagnosisPoor prognosisPrognostic valueDisease progressionPrognostic marker
1997
Prostatic ductal system in rats: Tissue‐specific expression and regional variation in stromal distribution of transforming growth factor‐β1
Nemeth J, Sensibar J, White R, Zelner D, Kim I, Lee C. Prostatic ductal system in rats: Tissue‐specific expression and regional variation in stromal distribution of transforming growth factor‐β1. The Prostate 1997, 33: 64-71. PMID: 9294629, DOI: 10.1002/(sici)1097-0045(19970915)33:1<64::aid-pros11>3.0.co;2-j.Peer-Reviewed Original ResearchConceptsProstatic ductal systemDuctal systemRat ventral prostateAlpha-smooth muscle actin-positive stromal cellsVentral prostateProstatic smooth muscleGrowth factor-β1Stromal-epithelial interactionsEpithelial cell deathNormal rat prostateCell deathEpithelial cell compartmentStromal cell fractionImmunohistochemical stainingSmooth muscleStromal distributionFactor-β1Rat prostateGrowth regulatory roleNormal prostateProximal ductPercoll gradient centrifugationProstateStromal cellsRT-PCR analysis
1996
Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression.
Kim I, Ahn H, Zelner D, Park L, Sensibar J, Lee C. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression. Endocrinology 1996, 10: 107-15. PMID: 8838150, DOI: 10.1210/mend.10.1.8838150.Peer-Reviewed Original ResearchConceptsReceptor messenger RNARat ventral prostateType II receptorII receptorsVentral prostateReceptor expressionDay 7Growth factor-beta receptor type IType III receptor expressionTGF betaTGF-beta receptor type IIType IType II receptor proteinType II receptor expressionMessenger RNAEffects of androgensTGF-beta signaling receptorsReceptor type IReceptor type IIStromal-epithelial interactionsType IIProstatic epithelial cellsGrowth factor beta receptorWestern blot analysisImmunohistochemical study